본문 바로가기
KERD
논문KCI 등재

주요우울장애에 대한 한약 단독치료의 효과와 안전성: 체계적문헌고찰 및 메타분석

Effectiveness and Safety of Traditional East Asian Herbal Medicine as Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis

김상호|권희주|승혜빈
대한한방신경정신과학회 (The Korean Society Of Oriental Neuropsychiatry)|2022.03|동의신경정신과학회지 (The Korean Society of Oriental Neuropsychiatry)|제33권 제1호|pp. 79-111|DOI 10.7231/jon.2022.33.1.079

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

Major depressive disorderMeta-analysisHerbal medicineAntidepressantComplementary Integrative medicine
주제분류한의학

초록

Major depressive disorder (MDD) causes a persistent feeling of sadness and loss of interest. It can lead to emotional and physical problems. Treatments such as antidepressant and cognitive behavioral therapy for MDD have many limitations. Traditional East Asian Herbal Medicine (TEAM) is a representative modality of Complementary and Integrative Medicine (CIM) which can be used for MDD. However, no study has systematically reviewed the efficacy or safety of TEAM for MDD so far. Therefore, we performed a systematic review and meta-analysis to evaluate effectiveness and safety of TEAM as a monotherapy for MDD. We only included TEAM that could be used in context of clinical setting in Korean Medicine. Outcomes were the Hamilton Depression Rating Scale (HAMD) and total effective rate (TER). After comprehensive electronic search of 11 databases, we included 28 randomized controlled trials (RCTs) that compared HM as monotherapy with antidepressant for MDD. Meta-analysis showed that TEAM had significant benefits in reducing HAMD (MD=-0.40, 95% CI: -0.67 to -0.13, p=0.003, I2=85%) and improving TER (RR=1.06, 95% CI: 1.02 to 1.10, p=0.003, I2=0%). It also appeared to be safer than antidepressant in terms of adverse effects. Methods used for RCTs were poor and the quality of evidence was graded ‘low’ or ‘moderate’. These findings indicate that the use of HM as a monotherapy might have potential benefits in MDD treatment as an alternative to antidepressant. However, considering the methodological quality of included RCTs, the clinical evidence is uncertain. Further well-designed RCTs are required to confirm these findings.

Abstract

Major depressive disorder (MDD) causes a persistent feeling of sadness and loss of interest. It can lead to emotional and physical problems. Treatments such as antidepressant and cognitive behavioral therapy for MDD have many limitations. Traditional East Asian Herbal Medicine (TEAM) is a representative modality of Complementary and Integrative Medicine (CIM) which can be used for MDD. However, no study has systematically reviewed the efficacy or safety of TEAM for MDD so far. Therefore, we performed a systematic review and meta-analysis to evaluate effectiveness and safety of TEAM as a monotherapy for MDD. We only included TEAM that could be used in context of clinical setting in Korean Medicine. Outcomes were the Hamilton Depression Rating Scale (HAMD) and total effective rate (TER). After comprehensive electronic search of 11 databases, we included 28 randomized controlled trials (RCTs) that compared HM as monotherapy with antidepressant for MDD. Meta-analysis showed that TEAM had significant benefits in reducing HAMD (MD=-0.40, 95% CI: -0.67 to -0.13, p=0.003, I2=85%) and improving TER (RR=1.06, 95% CI: 1.02 to 1.10, p=0.003, I2=0%). It also appeared to be safer than antidepressant in terms of adverse effects. Methods used for RCTs were poor and the quality of evidence was graded ‘low’ or ‘moderate’. These findings indicate that the use of HM as a monotherapy might have potential benefits in MDD treatment as an alternative to antidepressant. However, considering the methodological quality of included RCTs, the clinical evidence is uncertain. Further well-designed RCTs are required to confirm these findings.

참고문헌 (86)

  1. American Psychiatric Association, "Diagnosticand statistical manual of mental disorders: DSM-5", American Psychiatric Association, ~ (2013)
  2. Gutiérrez-Rojas L, "Prevalence and correlates of major depressive disorder : a systematic review", Braz J Psychiatry, 42(6), pp.657~672 (2020)[DOI]
  3. The epidemiological survey of mental disorders in Korea 2021, "Korean Ministry of Health and Welfare", Korean Ministry of Health and Welfare, ~ (2021)
  4. Liang S, "Incidence Trends and Risk Prediction Nomogram for Suicidal Attempts in Patients With Major Depressive Disorder", Front Psychiatry, 12, pp.644038~ (2021)[DOI]
  5. Hawton K, "Risk factors for suicide in individuals with depression : a systematic review", J Affect Disord, 147, pp.17~28 (2013)
  6. COVID-19 Mental Disorders Collaborators, "Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19pandemic", Lancet, 398(10312), pp.1700~1712 (2021)[DOI]
  7. "COVID-19 mental health survey of second quarter of 2021" (2021)[URL]
  8. Qaseem A, "Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder : a clinical practice guideline from the American College of Physicians", Annals of internal medicine, 164(5), pp.350~359 (2016)
  9. Carvalho AF, "The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs : A Critical Review of the Literature", Psychother Psychosom, 85(5), pp.270~288 (2016)[DOI]
  10. Cipriani A, "Comparative efficacy and acceptability of 12 new-generation antidepressants : a multiple-treatments meta-analysis", Lancet, 373(9665), pp.746~758 (2009)[DOI]
  11. Al-Harbi KS, "Treatment-resistant depression : therapeutic trends, challenges, and future directions", Patient Prefer Adherence, 6, pp.369~388 (2012)[DOI]
  12. Dubovicky M, "Risks of using SSRI", SNRI antidepressants during pregnancy and lactation, 2017, pp.10(1), 30~34
  13. Plöderl M, "Antidepressant prescription rates and suicide attempt rates from 2004 to 2016 in a nationally representative sample of adolescents in the USA", Epidemiology and Psychiatric Sciences, 28(5), pp.589~591 (2019)[DOI]
  14. Kok RM, "Management of Depression in Older Adults : A Review", JAMA, 317(20), pp.2114~2122 (2017)[DOI]
  15. Richardson K, "Polypharmacy including falls risk-increasing medications and subsequent falls in community-dwelling middle-aged and older adults", Age Ageing, 44(1), pp.90~96 (2015)[DOI]
  16. Sirey JA, "Stigma as a barrier to recovery : Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence", Psychiatr Serv, 52(12), pp.1615~1620 (2001)[DOI]
  17. Payne KA, "Increasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action", Healthc Policy, 5(3), pp.e173~e185 (2010)
  18. Haller H, "Complementary therapies for clinical depression : an overview of systematic reviews", BMJ Open, 9(8), pp.e028527~ (2019)[DOI]
  19. Wang Y, "Efficacy and safety of Chinese herbal medicine for depression : A systematic review and meta-analysis of randomized controlled trials", J Psychiatr Res, 117, pp.74~91 (2019)[DOI]
  20. Smith CA, "Acupuncture for depression", Cochrane Database Syst Rev, 3(3), pp.CD004046~ (2018)[DOI]
  21. The Textbook Compilation Committee of Neuropsychiatry of Oriental Medical Schools in Nation, "The Neuropsychiatry of Oriental medicine", pp.249~ (2016), Jipmoondang
  22. 한다영, "한약의 항우울 효과에 대한 국내 실험연구 고찰", 동의신경정신과학회지, 30(2), pp.71~88 (2019), 대한한방신경정신과학회[DOI]
  23. Yeung WF, "Prescription of Chinese Herbal Medicine in Pattern-Based Traditional Chinese Medicine Treatment for Depression : A Systematic Review", Evid Based Complement Alternat Med, 2015, pp.160189~ (2015)[DOI]
  24. Wang Y, "Efficacy and safety of Chinese herbal medicine for depression : A systematic review and meta-analysis of randomized controlled trials", J Psychiatr Res, 117, pp.74~91 (2019)[DOI]
  25. 안영성, "치매 및 우울증 고위험군 116례의 한의 치료에 대한 관찰 연구", 동의생리병리학회지, 35(3), pp.104~116 (2021), 한의병리학회
  26. Fumihiro Kawasaki, "Traditional Chinese medicine operation of Chinese medicine extract The role of Kamikihito for depressed patients with insomnia and bleeding", Traditional Chinese Medicine, 36(1), pp.60~63 (2015)
  27. Korean Institute of Oriental Medicine, "Korean Medicine Clinical Practice Guideline on Depression" (2015), Elsevier Korea L.L.C.
  28. Higgins, J., "Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0", pp.187~241 (2011), The Cochrane Collaboration
  29. Holger J Schünemann, "Grading quality of evidence and strength of recommendations for diagnostic tests and strategies", BMJ, 336(7653), pp.1106~1110 (2008), BMJ[DOI]
  30. Li LN, "Modified Banxia Houpu Decoction in the treatment of 35 cases of depression with predominant somatic symptoms", Fujian Chinese Medicine, 45(02), pp.24~25 (2014)
  31. Gu CH, "A multi-center randomized double-blind controlled trial of Jieyu Chufan capsules in the treatment of 334 cases of depression", Journal of Traditional Chinese Medicine, 8(57), pp.1297~1302 (2016)
  32. Wang TY, "Modified Danzhi Xiaoyao Decoction in the treatment of 34 cases of depression", Chinese Journal of Integrative Medicine, 21(09), pp.710~711 (2001)
  33. Tain Q, "Modified Danzhi Xiaoyao Decoction in the treatment of 48 cases of depression", Modern Chinese Medicine, 31(06), pp.10~11 (2011)
  34. Dou NJ, "Clinical observation of 50 cases of depression treated with Danzhi Xiaoyao Powder", China Medical Engineering, 20(09), pp.89~91 (2012)
  35. Yang CM, "Observation of 30 cases of mild to moderate depression treated with Xiaoyao Powder", Journal of Practical Chinese Medicine, 31(05), pp.381~ (2015)
  36. Hu YL, "Clinical study of Danzhi Xiaoyao Powder in the treatment of depression (anxiety and depression) with liver depression and qi stagnation syndrome", master, pp.2017
  37. He MX, "Observation and mechanism study of Danzhi Xiaoyao Powder in the treatment of mild to moderate depression", Famous Doctors, (02), pp.260~ (2019)
  38. Su R, "Jiawei Xiaoyao capsule treatment for mild to moderate major depression with anxiety symptoms : a randomized, double-blind, double-dummy, controlled, multicenter, parallel-treatment trial", J Tradit Chin Med, 39(3), pp.410~417 (2019)
  39. Xu TS, "A clinical study on 32 cases of depression treated with “Jianwei Ganmai Dazao Decoction”", Jiangsu Traditional Chinese Medicine, 43(09), pp.24~25 (2011)
  40. Zhao SQ, "Clinical observation of modified Ganmai Dazao decoction in the treatment of depression", Chinese Journal of Clinical Medicine, 24(08), pp.731~733 (2012)
  41. Zhu CJ, "Treatment of 30 cases of depression with deficiency of both heart and spleen by Guipi Decoction", Chinese Journal of Experimental Formulas, 20(16), pp.209~213 (2014)
  42. Zhang LS, "Clinical observation of modified Chaihu Longgu Muli Decoction in the treatment of depression", Hebei Medicine, 32(22), pp.3185~3186 (2010)
  43. Zhang Y, "Analysis on the effect of Chaihujia Longgu Muli Decoction in the treatment of depression", Journal of Contemporary Medicine, 12(15), pp.21~ (2014)
  44. Zhang Y, "Theoretical and clinical research on the treatment of depression with Chaihujia Longgu Muli Decoction", master, pp.2020
  45. Wang RC, "Clinical observation of Chaihu Shugan powder in the treatment of depression", Journal of Practical Chinese Medicine, 29(04), pp.258~259 (2013)
  46. Shao XQ, "Clinical Experience of 28 Cases of Depression Treated by Modified Chaihu Shugan Powder", World Latest Medical Information Digest, 16(53), pp.181~183 (2016)
  47. Zhang Y, "Chaihu Shugan Powder in the treatment of 43cases of liver-qi stagnation type depression syndrome", Modern distance education of traditional Chinese medicine in China, 14(24), pp.85~86 (2016)
  48. Zhang F, "60 cases of depression treated with modified Xiaoyao powder", Journal of Practical Chinese Medicine and Internal Medicine, 26(06), pp.37~38 (2012)
  49. Chen ZL, "The clinical effect of Jiajian Xiaoyao Powder in the treatment of depression due to liver stagnation and spleen deficiency", Integrative Chinese and Western Medicine Research, 8(6), pp.298~300 (2016)
  50. Zheng Q, "Clinical efficacy of Xiaoyao Powder in the treatment of mixed anxiety-depressive disorder with liver depression and spleen deficiency", Journal of Clinical Drug Therapy, 19(07), pp.60~64 (2021)
  51. Pan HF, "Clinical observation of Yueju Baohe Pill in the treatment of mild to moderate depression", Shizhen Chinese Medicine Chinese Medicine, 19(4), pp.887~889 (2008)
  52. Li ZP, "Yueju Shengjing Decoction in the treatment of 36 cases of mild to moderate depression", Liaoning Journal of Traditional Chinese Medicine, 37(08), pp.1522~1523 (2010)
  53. Mi JG, "A clinical study of Yueju Baohe Pill in the treatment of depression and its effect on plasma 5-HT content", Sichuan Traditional Chinese Medicine, 29(06), pp.61~63 (2011)
  54. Wang Y, "Clinical observation on 36 cases of senile depression treated with Yueju Shengjing Decoction", New Chinese Medicine, 44(6), pp.50~51 (2012)
  55. Li, Y.C., "The Influence of Yueju Shengjiang Decoction on Improving Somatic Symptoms and Psychological Disorders of Senile Melancholia", Henan Traditional Chinese Medicine, 35(1), pp.181~183 (2015)
  56. Li, R, "An effect of Yueju Wan on 5-hydroxy tryptamine of depression patients", Traditional Chinese Medicine Clinical Research, 8(22), pp.27~29 (2016)
  57. Zhang YX, "Randomized double-blind controlled trial of Yueju Pill in the treatment of depression combined with disease and syndrome", World Science and Technology, 22(9), pp.3283~3287 (2020)
  58. Yang L, "Managing Depression with Bupleurum chinense Herbal Formula: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", J Altern Complement Med, 26(1), pp.8~24 (2020)[DOI]
  59. Wang XL, "Canonical Chinese medicine formula Danzhi-Xiaoyao-San for treating depression: A systematic review and meta-analysis", J Ethnopharmacol, 287, pp.114960~ (2022)[DOI]
  60. Yan Sun, "Treatment of depression with Chai Hu Shu Gan San: a systematic review and meta-analysis of 42 randomized controlled trials", BMC Complementary and Alternative Medicine, 18(1), pp.66~ (2018), Springer Science and Business Media LLC[DOI]
  61. Chan Li, "Chinese Herbal Medicine for the Treatment of Depression: Effects on the Neuroendocrine-Immune Network", Pharmaceuticals, 14(1), pp.65~ (2021), MDPI AG[DOI]
  62. Boram Lee, "Herbal Medicine (Sihogayonggolmoryeo-Tang or Chai-Hu-Jia-Long-Gu-Mu-Li-Tang) for Treating Hypertension:A Systematic Review and Meta-Analysis", Evidence-Based Complementary and Alternative Medicine, 2020, pp.1~13 (2020), Hindawi Limited[DOI]
  63. Delgado PL, "Depression: the case for a monoamine deficiency", J Clin Psychiatry, 6(Suppl 6), pp.7~11 (2000)
  64. Guiqin Bai, "Anti-depressive effects of Jiao-Tai-Wan on CORT-induced depression in mice by inhibiting inflammation and microglia activation", Journal of Ethnopharmacology, 283, pp.114717~ (2022), Elsevier BV[DOI]
  65. R.S. Smith, "The macrophage theory of depression", Medical Hypotheses, 35(4), pp.298~306 (1991), Elsevier BV[DOI]
  66. Xiaoxia Gao, "Metabonomic study on chronic unpredictable mild stress and intervention effects of Xiaoyaosan in rats using gas chromatography coupled with mass spectrometry", Journal of Ethnopharmacology, 137(1), pp.690~699 (2011), Elsevier BV[DOI]
  67. Yucong Shi, "Identification of Potential Biomarkers of Depression and Network Pharmacology Approach to Investigate the Mechanism of Key Genes and Therapeutic Traditional Chinese Medicine in the Treatment of Depression", Evidence-Based Complementary and Alternative Medicine, 2021, pp.1~14 (2021), Hindawi Limited[DOI]
  68. Chen ZY, "Identification of the significant pathways of Banxia Houpu decoction in the treatment of depression based on network pharmacology", PLoS One, 15(9), pp.e0239843~ (2020)[DOI]
  69. Wu LL, "Antidepressant-Like Effects of Fractions Prepared from Danzhi-Xiaoyao-San Decoction in Rats with Chronic Unpredictable Mild Stress : Effects on Hypothalamic-Pituitary-Adrenal Axis, Arginine Vasopressin, and Neurotransmitters", Evid Based Complement Alternat Med, 2016, pp.6784689~ (2016)[DOI]
  70. Chan Li, "Traditional Chinese Medicine in Depression Treatment: From Molecules to Systems", Frontiers in Pharmacology, 11, pp.586~ (2020), Frontiers Media SA[DOI]
  71. Yang Jin, "Mechanisms of Panax ginseng action as an antidepressant", Cell Proliferation, 52(6), pp.e12696~ (2019), Wiley[DOI]
  72. Dinesh Dhingra, "Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests", Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(3), pp.449~454 (2006), Elsevier BV[DOI]
  73. Sunoh Kwon, "Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test", Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(2), pp.265~270 (2010), Elsevier BV[DOI]
  74. Xiuping Sun, "Total Saikosaponins of Bupleurum yinchowense reduces depressive, anxiety-like behavior and increases synaptic proteins expression in chronic corticosterine-treated mice", BMC Complementary and Alternative Medicine, 18(1), pp.117~ (2018), Springer Science and Business Media LLC[DOI]
  75. Chen KZ, , Zhongguo Zhong Yao Za Zhi, 46(19), pp.5088~5095 (2021)[DOI]
  76. The Textbook Compilation Committee of Herbal formula science of Oriental Medical Schools in Nation, "Herbal formula science in korean medicine", pp.258~268 (2020), Koonja Publisher
  77. 김상현, "울증(鬱證)의 개념 정립에 관한 문헌고찰", 동의신경정신과학회지, 31(2), pp.121~133 (2020), 대한한방신경정신과학회[DOI]
  78. 김국기, "우울증 생쥐 모델에서 半夏厚朴湯加味의 항우울 효과", 동의신경정신과학회지, 25(2), pp.191~202 (2014), 대한한방신경정신과학회
  79. Naito T, "Effect of Hange-koboku-to(Banxia-houpo-tang)on an plasma and saliva", Biol Pharm Bull, 26, pp.1609~1613 (2013)
  80. Kuribara H, "The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark", J Pharm Pharmacol, 52(11), pp.1425~1429 (2000)[DOI]
  81. Zheng Q, "Meta Analysis of the Clinical Efficacy of Banxia Houpu Decoction in the Treatment of Depression", Shandong University of Traditional Chinese Medicine, 18(43), pp.7~8 (2018)
  82. 이원융, "소요산의 방론에 대한 고찰", 대한한의학 방제학회지, 25(2), pp.209~222 (2017), 대한한의학방제학회[DOI]
  83. 신진영, "일차의료에서의 우울증", Korean Journal of Family Practice, 10(6), pp.401~406 (2020), 대한가정의학회[DOI]
  84. The Textbook Compilation Committee of Neuropsychiatry of Oriental Medical Schools in Nation, "The Neuropsychiatry of Oriental medicine", pp.581~ (2018), Maver Publisher
  85. SUN, Lingyun, "Evaluating Cancer Patients’ Expectations and Barriers Toward Traditional Chinese Medicine Utilization in China: A Patient-Support Group–Based Cross-Sectional Survey", Integrative cancer therapies, 17(3), pp.885~893 (2018)
  86. 이헌수, "우울증 변증도구의 신뢰도, 타당도 평가", 동의신경정신과학회지, 26(4), pp.407~416 (2015), 대한한방신경정신과학회

관련 논문AI추천

중풍후우울증에 대한 월국환의 효과와 안전성: 체계적 문헌고찰 및 메타분석김병진, 김상호대한한방신경정신과학회 · 동의신경정신과학회지2024 · 제35권 제4호우울증에 대한 한약물 치료 문헌적 고찰 - 무작위 대조군 임상연구를 중심으로 -권용주, 이재은, 조성훈대한한방신경정신과학회 · 동의신경정신과학회지2011 · 제22권 제4호뇌졸중 후 우울증에 대한 침과 한약의 결합 치료 효과: 체계적 문헌 고찰 및 메타분석 연구김상호, 임수연, 정대규, 사공종원대한한방신경정신과학회 · 동의신경정신과학회지2020 · 제31권 제3호우울장애 한약치료에 대한 전향적 관찰연구김환, 김주연, 양창섭, 이미영, 이지윤, 정인철, 정진형대한한방신경정신과학회 · 동의신경정신과학회지2020 · 제31권 제2호청소년기 우울증의 한약치료에 관한 주제범위 문헌고찰김상민, 김예지, 서혜선, 이선행, 이진용대한한방소아과학회 · 대한한방소아과학회지2022 · 제36권 제2호경증 및 아임상 우울증의 중의학 임상연구 동향 분석 - China National Knowledge Infrastructure를 중심으로 -고유미, 김상혁, 이시우대한예방한의학회 · 대한예방한의학회지2015 · 제19권 제1호

이 간행물의 다른 논문 (5건)

한방병원에 입원한 화병 환자의 정서적 특성에 대한 핵심칠정척도 단축형을 활용한 후향적 관찰연구정인철, 강동훈, 강형원, 김주연pp. 1-19상부위장관내시경 소견과 핵심칠정척도 단축형을 활용한 정서적 특성 연구한민석, 김광우, 강형원, 류영수, 고경진, 강성현pp. 21-31Effects of Emotion Freedom Techniques on Academic Stress in Korean Medical Students: A Single-Group Pre-Post Study채한, 한상윤, 임정화, 이수진, Seung Hwan Leepp. 33-48A Systematic Review and Meta-Analysis of Randomized Controlled Trials on Acupuncture for Improving Post-Operative Cognitive Dysfunction (POCD) and Chemotherapy-Related Cognitive Impairment (CRCI)Geun-Woo Kim, Ju-Young Kim, Han-Byul Cho, Man-Gi Kim, Byung-Su Koopp. 49-78심한 상열감으로 인한 불면을 호소하는 환자의 한의 치료 1례: 증례보고김경옥, 김보성, 배진수, 장에스더, 안선주pp. 113-122
원문 보기